Vadastuximab talirine: mechanism of action and combination with hypomethylating agents
Relapse in DLBCL - addressing the unmet need with brentuximab vedotin
Highlights from ICML 2017: The CLL2-BAG study
Highlights from ASH 2016: whole-genome sequencing to identify genomic lesions in ALL
Are combination therapies more effective for the treatment of relapsed refractory CLL?